• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Shockwave Medical Inc.

    6/10/24 4:33:25 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care
    Get the next $SWAV alert in real time by email
    15-12G 1 d825188d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number 001-38829

     

     

    Shockwave Medical, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    5403 Betsy Ross Drive

    Santa Clara, California 95054

    (510) 279-4262

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, par value $0.001 per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: Two (2)

    Pursuant to the requirements of the Securities Exchange Act of 1934, Shockwave Medical, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

        Shockwave Medical, Inc.
    Date: June 10, 2024     By:   /s/ Laura H. McFalls
          Name: Laura H. McFalls
          Title:  Assistant Secretary

     

     

     

    Get the next $SWAV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWAV

    DatePrice TargetRatingAnalyst
    4/5/2024Outperform → Peer Perform
    Wolfe Research
    3/27/2024$368.00Buy
    CL King
    9/29/2023$218.00Neutral
    UBS
    7/10/2023$291.00 → $335.00Equal-Weight → Overweight
    Morgan Stanley
    5/30/2023$291.00Equal-Weight
    Morgan Stanley
    3/15/2023$240.00Buy
    Needham
    12/16/2022$285.00Buy
    Deutsche Bank
    12/12/2022$300.00 → $235.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ShockWave Medical downgraded by Wolfe Research

      Wolfe Research downgraded ShockWave Medical from Outperform to Peer Perform

      4/5/24 7:33:47 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • CL King initiated coverage on ShockWave Medical with a new price target

      CL King initiated coverage of ShockWave Medical with a rating of Buy and set a new price target of $368.00

      3/27/24 8:20:17 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on ShockWave Medical with a new price target

      UBS initiated coverage of ShockWave Medical with a rating of Neutral and set a new price target of $218.00

      9/29/23 7:46:27 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Sarepta Therapeutics Set to Join S&P MidCap 400

      NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector June 3, 2024 S&P MidCap 400 Addition Sarepta Therapeutics SRPT Health Care June 3, 2024 S&P MidCap 400 Deletion Shockwave Medical SWAV Health Care For

      5/29/24 5:48:00 PM ET
      $JNJ
      $SPGI
      $SRPT
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance

    $SWAV
    Financials

    Live finance-specific insights

    See more
    • Shockwave Medical Reports First Quarter 2024 Financial Results

      SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to

      5/6/24 4:05:00 PM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Johnson & Johnson to Acquire Shockwave Medical

      Enhances Johnson & Johnson's Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech's Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ) and Shockwave Medical, Inc. (NASDAQ:SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335

      4/5/24 6:31:00 AM ET
      $JNJ
      $SWAV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results

      SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheterGranted new physician and hospital reimbursement for

      2/15/24 4:03:00 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    SEC Filings

    See more
    • SEC Form 15-12G filed by Shockwave Medical Inc.

      15-12G - Shockwave Medical, Inc. (0001642545) (Filer)

      6/10/24 4:33:25 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:38:18 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Shockwave Medical Inc.

      S-8 POS - Shockwave Medical, Inc. (0001642545) (Filer)

      5/31/24 4:28:57 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:42:11 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:41:41 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Shockwave Medical, Inc. (0001642545) (Issuer)

      5/31/24 4:40:07 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care

    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/13/24 5:13:59 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/9/24 9:49:30 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by ShockWave Medical Inc.

      SC 13G - Shockwave Medical, Inc. (0001642545) (Subject)

      2/8/24 10:17:35 AM ET
      $SWAV
      Medical/Dental Instruments
      Health Care